Concepedia

M. Fernández

MF

Statistics

Publications

5

Citations

172

H-Index

5

Active since

2017

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Samsung Medical Center

Osaka National Hospital

The Cancer Institute Hospital

Asan Medical Center

M. Fernández is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and pembrolizumab therapy.

ORCID

Publications per year

2017–2025

5

Publications

5

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial

Fátima Cardoso, Joyce O’Shaughnessy, Zhenzhen Liu et al. · Nature Medicine · 2025 · 114 citations · Full text

, , +17

Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

Fátima Cardoso, Joyce O’Shaughnessy, Heather L. McArthur et al. · Cancer Research · 2024 · 16 citations

, , +17

Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study

Juan Moróte, Á. Tabernero, J.L. Álvarez Ossorio et al. · International Journal of Radiation Oncology*Biology*Physics · 2017 · 15 citations

, , +15

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

Jin Li, M. Fernández, Felipe Reyes-Cosmelli et al. · Journal of Clinical Oncology · 2025 · 15 citations · Full text

, , +16

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.

Sun Young Rha, Lucjan Wyrwicz, P.E. Yanez Weber et al. · Journal of Clinical Oncology · 2023 · 12 citations

, , +12

1–5 of 5